Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25514472 | 0.85 | PTPN11 (0.48) | PTPN11KCNH2EGFR | |
| SCHEMBL21115151 | 0.84 | PTPN11 (0.52) | PTPN11KCNH2EGFR | |
| SCHEMBL19785077 | 0.84 | PTPN11 (0.52) | PTPN11KCNH2EGFR | |
| SCHEMBL19785556 | 0.84 | PTPN11 (0.51) | PTPN11KCNH2EGFR | |
| SCHEMBL23425262 | 0.84 | PTPN11 (0.51) | PTPN11KCNH2EGFRPLAUFFAR4 | |
| SCHEMBL21154711 | 0.84 | PTPN11 (0.49) | PTPN11KCNH2EGFRCD274PDCD1 | |
| SCHEMBL19785090 | 0.82 | PTPN11 (0.58) | PTPN11KCNH2EGFR | |
| SCHEMBL19785545 | 0.77 | PTPN11 (0.54) | PTPN11KCNH2EGFR | |
| SCHEMBL25514635 | 0.74 | PTPN11 (0.45) | PTPN11KCNH2EGFRPLAU | |
| SCHEMBL25514461 | 0.74 | PTPN11 (0.58) | PTPN11KCNH2EGFRCD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3484856-B1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. | 2021-05-27 | — | — | US | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210154190-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | PTPN1, PTPN18, PTPN7 | PTPN11 15/4885KCNH2 4135/4885EGFR 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.